Avalo Therapeutics Inc. Company Profile
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 13.43 0.00%
Avalo Therapeutics at a glance
Avalo Therapeutics Inc. (NASDAQ: AVTX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Wayne, PA. Avalo Therapeutics is led by Dr. Garry A. Neil M.D. and employs about 33 people. The company's shares have traded publicly since 2015.
At a market capitalization of $728.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001534120, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Avalo Therapeutics do?
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Avalo Therapeutics Inc.
- Ticker
- NASDAQ: AVTX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Garry A. Neil M.D.
- Employees
- 33
- Headquarters
- 1500 Liberty Ridge Drive, Wayne, PA, United States
- Phone
- 410 522 8707
- Website
- avalotx.com
- IPO year
- 2015
- Market cap
- $728.30M
- SEC CIK
- 0001534120
Companies similar to Avalo Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VSTMVerastem Inc. | 8.11 | -1.88% | $734.47M | vs AVTX |
| COLLCollegium Pharmaceutical Inc. | 22.11 | +0.82% | $719.80M | vs AVTX |
| DSGNDesign Therapeutics Inc. | 11.49 | -1.71% | $719.06M | vs AVTX |
| GYREGyre Therapeutics Inc. | 6.76 | -3.98% | $716.79M | vs AVTX |
| OBXObsidian Therapeutics Inc. | 12.24 | -7.27% | $756.10M | vs AVTX |
| ANNXAnnexon Inc. | 4.00 | -0.25% | $758.32M | vs AVTX |
| APMDApnimed Inc. | 18.22 | +1.00% | $758.51M | vs AVTX |
| IMMXImmix Biopharma Inc. | 9.29 | -2.11% | $770.17M | vs AVTX |